Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...

ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed ...

Immunoglobulin 4-related disease (IgG4-RD) is known for its potential to affect nearly every organ, particularly a preference for large and middle-sized arteries when vascular involvement occurs.

which is in a phase 3 trial as a treatment for IgG4-related disease (IgG4-RD), phase 2/3 in warm autoimmune haemolytic anaemia (wAIHA), and phase 2 in multiple sclerosis (MS) and systemic lupus ...

Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...